- Home
- NURO vs ALZN Comparison
NURO vs ALZN Comparison
Compare NURO & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NURO
- ALZN
- Stock Information
- Founded
- NURO 1996
- ALZN 2016
- Country
- NURO United States
- ALZN United States
- Employees
- NURO N/A
- ALZN N/A
- Industry
- NURO Medical/Dental Instruments
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- NURO Health Care
- ALZN Health Care
- Exchange
- NURO Nasdaq
- ALZN Nasdaq
- Market Cap
- NURO 7.6M
- ALZN 7.0M
- IPO Year
- NURO N/A
- ALZN 2021
- Fundamental
- Price
- NURO $3.93
- ALZN $1.35
- Analyst Decision
- NURO
- ALZN Strong Buy
- Analyst Count
- NURO 0
- ALZN 1
- Target Price
- NURO N/A
- ALZN $35.00
- AVG Volume (30 Days)
- NURO 21.2K
- ALZN 128.2K
- Earning Date
- NURO 11-05-2024
- ALZN 12-13-2024
- Dividend Yield
- NURO N/A
- ALZN N/A
- EPS Growth
- NURO N/A
- ALZN N/A
- EPS
- NURO N/A
- ALZN N/A
- Revenue
- NURO $3,767,764.00
- ALZN N/A
- Revenue This Year
- NURO N/A
- ALZN N/A
- Revenue Next Year
- NURO N/A
- ALZN N/A
- P/E Ratio
- NURO N/A
- ALZN N/A
- Revenue Growth
- NURO N/A
- ALZN N/A
- 52 Week Low
- NURO $2.66
- ALZN $1.40
- 52 Week High
- NURO $4.73
- ALZN $19.20
- Technical
- Relative Strength Index (RSI)
- NURO 45.39
- ALZN 38.66
- Support Level
- NURO $3.56
- ALZN $1.43
- Resistance Level
- NURO $3.80
- ALZN $1.59
- Average True Range (ATR)
- NURO 0.30
- ALZN 0.09
- MACD
- NURO -0.03
- ALZN 0.00
- Stochastic Oscillator
- NURO 37.75
- ALZN 15.38
About NURO NeuroMetrix Inc.
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.